ImmunityBio Confirms Statistical Power in Pivotal Randomized BCG-Naïve NMIBC Trial to Detect Clinically Meaningful Differences Between ANKTIVA® Plus BCG Versus BCG Alone; Supplemental BLA Submission
Go back to ImmunityBio Confirms Statistical Power in Pivotal Randomized BCG-Naïve NMIBC Trial to Detect Clinically Meaningful Differences Between ANKTIVA® Plus BCG Versus BCG Alone; Supplemental BLA Submission| (NASDAQ: IBRX) | Delayed: 7.36 +0.37 (5.29%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $6.99 | 52 Week High | $ | |||
| Open | $7.15 | 52 Week Low | $ | |||
| Day High | $7.46 | P/E | N/A | |||
| Day Low | $7.03 | EPS | $ | |||
| Volume | 14,372,401 | |||||
